Concerns over incidence of liver toxicity in patients taking Arava®

There has been recent concerns about liver failure and death in patients taking Arava^®. These concerns emanated from the European reports which are summarized on the European Medicines Evaluation Agency’s (EMEA) Website. A number of patients who developed liver disease or died when taking Arava^® had pre-existing liver disease and/or were on other hepatotoxic drugs. Extreme caution should be used in these patients. For more information, please see the American College of Rheumatology and the European Medicines Evaluation Agency’s (EMEA) Websites